Syndax Pharmaceuticals, Inc.

From Syndax Pharmaceuticals's results release of 2026年11月2日; its quarterly report has since been filed.

• Revenue

  Actual

  $83.3M

  +82% y/y ↑
  +14% q/q ↑

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  -$0.55

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  -$41.9M

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.